124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis
Status:
Completed
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
This is a single-center, exploratory, Phase 1 Positron Emission Tomography/x-ray Computed
Tomography (PET/CT) imaging study to detect amyloidosis that will enroll patients with a
confirmed diagnosis of systemic amyloidosis. The purpose of this exploratory trial is to
assess the safety and efficacy of 124I-p5+14 Injection at a single-injection dose adequate
for imaging amyloid deposits by using PET/CT imaging in subjects with confirmed systemic
Immunoglobulin Light Chain-associated Amyloidosis (AL), Transthyretin-associated Amyloidosis
(ATTR), Leukocyte Chemotactic Factor 2-associated Amyloidosis (ALect2) as well as other
types.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Tennessee Graduate School of Medicine